Literature DB >> 8150347

Frequency of glucocorticoid resistance and dependency in Crohn's disease.

P Munkholm1, E Langholz, M Davidsen, V Binder.   

Abstract

The outcome of the first steroid treatment course was prospectively studied in a regional cohort of 196 patients with Crohn's disease diagnosed 1979-1987. The immediate outcome after 30 days, and the prolonged outcome 30 days after treatment had stopped, are described. In all 109 patients treatment was analysed. Complete remission was obtained in 48%, partial remission in 32%, and no response in 20% within 30 days of treatment. Among primary responders (complete and partial remission), 55% remained in prolonged response after treatment had finished, while 45% relapsed or could not be withdrawn from treatment within one year. Localisation of disease, age, sex or clinical symptoms did not significantly correlate with outcome, which can be summarised as prolonged steroid response in 44%, steroid dependency in 36%, and steroid resistant in 20% of the patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8150347      PMCID: PMC1374590          DOI: 10.1136/gut.35.3.360

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  8 in total

1.  Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: a sixfold increase in incidence.

Authors:  P Munkholm; E Langholz; O H Nielsen; S Kreiner; V Binder
Journal:  Scand J Gastroenterol       Date:  1992-07       Impact factor: 2.423

Review 2.  Toward optimal use of corticosteroids in ulcerative colitis and Crohn's disease.

Authors:  J E Lennard-Jones
Journal:  Gut       Date:  1983-03       Impact factor: 23.059

3.  National Cooperative Crohn's Disease Study: results of drug treatment.

Authors:  R W Summers; D M Switz; J T Sessions; J M Becktel; W R Best; F Kern; J W Singleton
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

4.  National Cooperative Crohn's Disease Study: adverse reactions to study drugs.

Authors:  J W Singleton; D H Law; M L Kelley; H S Mekhjian; R A Sturdevant
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

5.  Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

Authors:  R Modigliani; J Y Mary; J F Simon; A Cortot; J C Soule; J P Gendre; E Rene
Journal:  Gastroenterology       Date:  1990-04       Impact factor: 22.682

6.  Development of new glucocorticosteroids with a very high ratio between topical and systemic activities.

Authors:  R Brattsand; A Thalén; K Roempke; L Källström; E Gruvstad
Journal:  Eur J Respir Dis Suppl       Date:  1982

7.  European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment.

Authors:  H Malchow; K Ewe; J W Brandes; H Goebell; H Ehms; H Sommer; H Jesdinsky
Journal:  Gastroenterology       Date:  1984-02       Impact factor: 22.682

8.  Metabolic pathways of the topical glucocorticoid budesonide in man.

Authors:  S Edsbäcker; S Jönsson; C Lindberg; A Ryrfeldt; A Thalén
Journal:  Drug Metab Dispos       Date:  1983 Nov-Dec       Impact factor: 3.922

  8 in total
  95 in total

Review 1.  Anti-TNF antibody treatment of Crohn's disease.

Authors:  S J van Deventer
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  [Clinical effectiveness of various budesonide preparations in Crohn disease].

Authors:  J Schölmerich
Journal:  Med Klin (Munich)       Date:  1999-02-15

Review 3.  New steroids and new salicylates in inflammatory bowel disease: a critical appraisal.

Authors:  M Campieri
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

4.  Inflammatory Bowel Disease: Future Therapies.

Authors:  Sander J.H. Van Deventer
Journal:  Curr Treat Options Gastroenterol       Date:  2002-06

5.  Treatment of Crohn's Disease of Inflammatory, Stenotic, and Fistulizing Phenotypes.

Authors:  Marla C. Dubinsky; Phillip P. Fleshner
Journal:  Curr Treat Options Gastroenterol       Date:  2003-06

6.  Choosing Therapy on the Basis of Disease Classifications in Inflammatory Bowel Disease.

Authors:  Maria T. Abreu
Journal:  Curr Treat Options Gastroenterol       Date:  2004-06

7.  Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density.

Authors:  M T Abreu; V Kantorovich; E A Vasiliauskas; U Gruntmanis; R Matuk; K Daigle; S Chen; D Zehnder; Y-C Lin; H Yang; M Hewison; J S Adams
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

8.  Optimal use of biologics in the management of Crohn's disease.

Authors:  Remo Panaccione; Subrata Ghosh
Journal:  Therap Adv Gastroenterol       Date:  2010-05       Impact factor: 4.409

9.  Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial.

Authors:  T Andus; V Gross; I Caesar; H J Schulz; H Lochs; W D Strohm; M Gierend; A Weber; K Ewe; J Schölmerich
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

Review 10.  Medical management of crohn disease.

Authors:  Frank I Scott; Mark T Osterman
Journal:  Clin Colon Rectal Surg       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.